KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Receivables - Other (2018 - 2024)

Halozyme Therapeutics (HALO) has disclosed Receivables - Other for 7 consecutive years, with $20.3 million as the latest value for Q4 2024.

  • Quarterly Receivables - Other rose 1930.0% to $20.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Dec 2024, up 1930.0% year-over-year, with the annual reading at $20.3 million for FY2024, 1930.0% up from the prior year.
  • Receivables - Other for Q4 2024 was $20.3 million at Halozyme Therapeutics, up from $1.0 million in the prior quarter.
  • The five-year high for Receivables - Other was $69.2 million in Q3 2022, with the low at $243000.0 in Q2 2023.
  • Average Receivables - Other over 5 years is $20.5 million, with a median of $15.1 million recorded in 2022.
  • The sharpest move saw Receivables - Other crashed 97.57% in 2023, then surged 1930.0% in 2024.
  • Over 5 years, Receivables - Other stood at $7.0 million in 2020, then skyrocketed by 328.57% to $30.0 million in 2021, then skyrocketed by 130.67% to $69.2 million in 2022, then crashed by 98.55% to $1.0 million in 2023, then soared by 1930.0% to $20.3 million in 2024.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $20.3 million, $1.0 million, and $3.3 million for Q4 2024, Q4 2023, and Q3 2023 respectively.